Combating Violence Against Women

June 24, 2025 updated by: Fatma Yildirim, Hitit University

The Effect of the Programme on Combating Violence Against Women on Domestic Violence Awareness and Gender Attitudes: A Randomized Controlled Trial

The aim of the study was to investigate the effect of the program to combat violence against women on domestic violence awareness and gender role attitudes.

Study Overview

Status

Enrolling by invitation

Conditions

Detailed Description

Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale will be used in collecting research data.

After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.

No intervention will be made to the control group.

Study Type

Interventional

Enrollment (Estimated)

62

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Çorum, Turkey
        • Ordu University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women between the ages of 18-45,
  • Who speaks Turkish,
  • Who has previously applied to law enforcement due to violence,
  • Women who volunteer to participate in the research.

Exclusion Criteria:

  • Women diagnosed with a psychiatric illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active Comparator: Control group
All women will be given the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale as a pre-test. No intervention will be made to the control group. After 8 weeks, all women will be reunited and given the Domestic Violence Awareness Scale and Gender Role Attitude Scale as a post-test.

After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.

8 weeks after the completion of the training, all women will be reunited and the Domestic Violence Awareness Scale and Gender Role Attitude Scale will be applied as a post-test.

Experimental: Combating violence against women

After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.

8 weeks after the completion of the training, all women will be reunited and the Domestic Violence Awareness Scale and Gender Role Attitude Scale will be applied as a post-test.

After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.

8 weeks after the completion of the training, all women will be reunited and the Domestic Violence Awareness Scale and Gender Role Attitude Scale will be applied as a post-test.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Domestic Violence Awareness Scale
Time Frame: 2 months
The scale developed by Özyürek and Kurnaz (2019) consists of 20 items measuring awareness of domestic violence on a three-point Likert scale. The highest score that can be obtained from each item is three, and the lowest score is one. Items 1-5 in the scale constitute the sub-dimensions of "Definition of Domestic Violence", items 6-10 constitute the sub-dimensions of "Consequences of Domestic Violence", items 11-15 constitute the sub-dimensions of "Acceptance of Domestic Violence", and items 16-20 constitute the sub-dimensions of "Normalization of Domestic Violence". High total scores obtained from the entire scale can be interpreted as the individual having views compatible with the expected behaviors and attitudes in scientific and legal fields in interpreting domestic violence and having a high level of awareness of domestic violence. The Cronbach alpha coefficient of the scale was reported to be 0.92 and ranged between 0.71 and 0.92 for its sub-dimensions. In this study, Cronbach
2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gender Roles Attitude Scale
Time Frame: 2 months
Gender Roles Scale was originally developed by García-Cueto and colleagues (2015). Adaptation of the scale to Turkish and reliability validity study were conducted by Bakioğlu and Türküm (2019). In the original study, Cronbach alpha internal consistency coefficient was calculated as 0.99 within the scope of reliability of the scale, in the adaptation study, Cronbach alpha internal consistency coefficient was calculated as 0.88 and test-retest reliability was calculated as 0.77. The scale consists of 15 questions and a single dimension. The items are answered in Likert type as 1= I completely disagree, 2= I disagree, 3= I am undecided, 4= I agree, 5= I completely agree and so on. The 13 items of the scale, except for items 1 and 2, are reverse coded. A total score is obtained from the scale, and a higher score indicates a higher negative attitude towards gender roles. In other words, a person who scores high on the scale adopts gender roles less and shows less commitment than a person
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 28, 2025

Primary Completion (Estimated)

July 28, 2025

Study Completion (Estimated)

September 15, 2025

Study Registration Dates

First Submitted

June 13, 2025

First Submitted That Met QC Criteria

June 24, 2025

First Posted (Actual)

July 3, 2025

Study Record Updates

Last Update Posted (Actual)

July 3, 2025

Last Update Submitted That Met QC Criteria

June 24, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • Combating Violence Against Wom

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data will be shared with researchers who apply for appropriate use for research purposes only, with ethics committee approval.

IPD Sharing Time Frame

after publication

IPD Sharing Access Criteria

Researchers who are conducting research in the same field and have received ethics committee approval.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nursing Role

Clinical Trials on Experimental: Experimental: Combating violence against women

3
Subscribe